Table 2 Univariate analysis for overall survival and disease free survival

Nrf2

<0.01

<0.01

 Low

30.40 ± 4.16

22.25-38.56

24.43 ± 3.33

17.90-30.96

 High

13.87 ± 0.95

12.02-15.73

11.24 ± 0.76

9.75-12.73

Gender

0.93

0.91

 Male

17.56 ± 1.32

14.97-20.15

15.43 ± 2.91

9.72-21.13

 Female

19.07 ± 3.64

11.94-26.20

14.15 ± 1.05

12.08-16.22

Age

0.94

0.91

 <60

18.98 ± 2.50

14.08-23.88

15.33 ± 1.99

11.43-19.23

 ≥60

18.43 ± 2.31

13.90-22.97

14.93 ± 1.86

11.29-18.56

Metastasis

<0.01

<0.01

 Negative

22.56 ± 2.48

17.69-27.42

18.18 ± 1.99

14.29-22.07

 Positive

12.97 ± 1.18

10.66-15.29

10.47 ± 0.93

8.64-12.30

Differentiation

0.01

0.02

 Well + Moderate

22.13 ± 2.52

17.20-27.07

17.81 ± 2.01

13.87-21.75

 Poor

13.51 ± 1.22

11.12-15.89

10.94 ± 0.92

9.02-12.87

HBV infection

0.69

0.70

 Negative

19.64 ± 3.90

12.00-27.29

15.89 ± 3.07

9.87-21.92

 Positive

18.80 ± 2.02

14.83-22.77

15.24 ± 1.65

12.01-18.47

Liver cirrhosis

0.09

0.10

 No

21.09 ± 2.22

16.73-25.44

17.09 ± 1.77

13.62-20.56

 Yes

17.24 ± 2.13

13.07-21.40

13.90 ± 1.70

10.56-17.23

AFP

0.20

0.19

 ≤400 μg/L

20.84 ± 2.02

16.88-24.79

16.82 ± 1.62

13.65-19.99

 >400 μg/L

17.78 ± 2.27

13.35-22.22

14.36 ± 1.81

10.80-17.91

Tumor size

0.09

0.10

 <5 cm

21.98 ± 2.77

16.55-27.41

17.72 ± 2.22

13.38-22.06

 ≥5 cm

15.25 ± 1.56

12.18-18.31

12.35 ± 1.27

9.85-14.85

Tumor number

0.60

0.57

 Single

20.21 ± 2.71

14.89-25.52

16.35 ± 2.19

12.06-20.63

 multiple

16.83 ± 1.79

13.32-20.35

13.63 ± 1.43

10.84-16.43